Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $471,814 - $839,429
-23,311 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $1.21 Million - $1.78 Million
-46,689 Reduced 66.7%
23,311 $746,000
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $2.1 Million - $2.6 Million
70,000 New
70,000 $2.16 Million
Q3 2020

Nov 16, 2020

SELL
$35.98 - $47.66 $190,693 - $252,597
-5,300 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $25,991 - $52,234
-700 Reduced 11.67%
5,300 $380,000
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $236,160 - $460,800
6,000 New
6,000 $236,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $280M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Highland Capital Management Fund Advisors, L.P. Portfolio

Follow Highland Capital Management Fund Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.